miltefosine has been researched along with Breast Neoplasms in 28 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Breast Neoplasms: Tumors or cancer of the human BREAST.
Excerpt | Relevance | Reference |
---|---|---|
"Patients with previously treated progressive cutaneous lesions from breast cancer were treated with miltefosine on a named-patient compassionate supply basis." | 9.09 | Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. ( Clive, S; Gardiner, J; Leonard, RC, 1999) |
"To compare 6% miltefosine solution (Miltex; Asta Medica, Frankfurt, Germany), a new topical cytostatic drug, with placebo as palliative treatment for cutaneous metastases from breast cancer." | 9.09 | Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. ( David, M; Hardy, J; Houston, S; Leonard, R; Mansi, J; Simmonds, P; van Tienhoven, G, 2001) |
"This study describes the molecular signaling involved in the different cell death modes of triple-negative breast cancer cells induced by hexadecylphosphocholine (HePC/miltefosine), a clinically relevant anticancer alkylphosphocholine." | 7.74 | Distinctive molecular signaling in triple-negative breast cancer cell death triggered by hexadecylphosphocholine (miltefosine). ( Chakrabandhu, K; Huault, S; Hueber, AO, 2008) |
"Miltefosine was selected because of its efficacy in breast cancer models." | 6.69 | Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer. ( Beijnen, JH; Mandjes, IA; Sindermann, H; ten Bokkel Huinink, WW; Terwogt, JM, 1999) |
"Miltefosine therapy was discontinued in two patients due to nausea and in one patient due to skin toxicity." | 6.69 | Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. ( Bontenbal, M; Planting, AS; Seynaeve, C; Sindermann, H; Smorenburg, CH; Verweij, J, 2000) |
"Patients with previously treated progressive cutaneous lesions from breast cancer were treated with miltefosine on a named-patient compassionate supply basis." | 5.09 | Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma. ( Clive, S; Gardiner, J; Leonard, RC, 1999) |
"To compare 6% miltefosine solution (Miltex; Asta Medica, Frankfurt, Germany), a new topical cytostatic drug, with placebo as palliative treatment for cutaneous metastases from breast cancer." | 5.09 | Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer. ( David, M; Hardy, J; Houston, S; Leonard, R; Mansi, J; Simmonds, P; van Tienhoven, G, 2001) |
"This study describes the molecular signaling involved in the different cell death modes of triple-negative breast cancer cells induced by hexadecylphosphocholine (HePC/miltefosine), a clinically relevant anticancer alkylphosphocholine." | 3.74 | Distinctive molecular signaling in triple-negative breast cancer cell death triggered by hexadecylphosphocholine (miltefosine). ( Chakrabandhu, K; Huault, S; Hueber, AO, 2008) |
"Miltefosine (hexadecylphosphocholine) is used for topical treatment of breast cancers." | 3.71 | MDR1 causes resistance to the antitumour drug miltefosine. ( Grunicke, H; Hofmann, J; Liu, R; Lu, P; Pietro, AD; Rybczynska, M; Sharom, FJ; Spitaler, M; Steinfels, E, 2001) |
"Miltefosine was selected because of its efficacy in breast cancer models." | 2.69 | Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer. ( Beijnen, JH; Mandjes, IA; Sindermann, H; ten Bokkel Huinink, WW; Terwogt, JM, 1999) |
"Miltefosine therapy was discontinued in two patients due to nausea and in one patient due to skin toxicity." | 2.69 | Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. ( Bontenbal, M; Planting, AS; Seynaeve, C; Sindermann, H; Smorenburg, CH; Verweij, J, 2000) |
"D-19391 was added to the SK-BR-3 breast cancer cell line and HePC to the Molt-4 leukemia cell line in concentrations of, respectively, 18." | 1.30 | Cellular uptake and retention measurements of alkylphosphocholines in the SK-BR-3 breast cancer and Molt-4 leukemia cell line using capillary gas chromatography. ( Brochez, V; De Potter, CR; Diniz, JA; Van den Eeckhout, EG; Van Heuverswyn, D, 1999) |
" Conventional non-compartmental pharmacokinetic analysis and an elaborate three- and four-compartmental model were used for explaining the experimental data." | 1.30 | Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice. ( Arndt, D; Fahr, A; Fichtner, I; Teppke, AD; Zeisig, R, 1999) |
"Suramin has shown antitumour activity in vitro and in vivo." | 1.29 | The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin. ( Lopez Lopez, R; Peters, GJ; Pinedo, HM; van Rijswijk, RE; Wagstaff, J, 1994) |
"Widespread local recurrence of breast cancer, untreatable by surgery or radiation therapy, can present a serious therapeutic problem predominantly in patients refractory to systemic therapy." | 1.28 | Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. ( Eibl, H; Hilgard, P; Nagel, G; Peukert, M; Sindermann, H; Unger, C, 1990) |
" After oral application He-PC was well absorbed from the intestine and metabolized in the liver by phospholipases C and D." | 1.28 | Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo. ( Breiser, A; Damenz, W; Eibl, H; Engel, J; Fleer, EA; Hilgard, P; Kim, DJ; Nagel, G; Unger, C, 1989) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (7.14) | 18.7374 |
1990's | 19 (67.86) | 18.2507 |
2000's | 5 (17.86) | 29.6817 |
2010's | 1 (3.57) | 24.3611 |
2020's | 1 (3.57) | 2.80 |
Authors | Studies |
---|---|
Jangir, S | 1 |
Bala, V | 1 |
Lal, N | 1 |
Kumar, L | 1 |
Sarswat, A | 1 |
Kumar, A | 1 |
Saini, KS | 1 |
Sharma, V | 1 |
Verma, V | 1 |
Maikhuri, JP | 1 |
Konwar, R | 1 |
Gupta, G | 1 |
Sharma, VL | 1 |
El-Sheridy, NA | 1 |
El-Moslemany, RM | 1 |
Ramadan, AA | 1 |
Helmy, MW | 1 |
El-Khordagui, LK | 1 |
Chakrabandhu, K | 1 |
Huault, S | 1 |
Hueber, AO | 1 |
Lopez Lopez, R | 1 |
van Rijswijk, RE | 1 |
Wagstaff, J | 1 |
Pinedo, HM | 1 |
Peters, GJ | 1 |
Fichtner, I | 5 |
Zeisig, R | 4 |
Naundorf, H | 2 |
Jungmann, S | 1 |
Arndt, D | 4 |
Asongwe, G | 1 |
Double, JA | 1 |
Bibby, MC | 2 |
Bruyneel, EA | 1 |
Storme, GA | 1 |
Schallier, DC | 1 |
Van den Berge, DL | 1 |
Hilgard, P | 5 |
Mareel, MM | 1 |
Colombo, DT | 2 |
Tran, LK | 2 |
Reitz, RC | 2 |
Clive, S | 2 |
Leonard, RC | 2 |
Eue, I | 1 |
Sternberg, B | 1 |
Safa, O | 1 |
Parkin, SM | 1 |
Speck, JJ | 1 |
Stahn, R | 1 |
Terwogt, JM | 1 |
Mandjes, IA | 1 |
Sindermann, H | 5 |
Beijnen, JH | 1 |
ten Bokkel Huinink, WW | 1 |
Brochez, V | 1 |
Van Heuverswyn, D | 1 |
Diniz, JA | 1 |
De Potter, CR | 1 |
Van den Eeckhout, EG | 1 |
Gardiner, J | 1 |
Teppke, AD | 1 |
Fahr, A | 1 |
Smorenburg, CH | 1 |
Seynaeve, C | 1 |
Bontenbal, M | 1 |
Planting, AS | 1 |
Verweij, J | 1 |
Moĭseenko, VM | 1 |
Orlova, RV | 1 |
Ermakova, NA | 1 |
Protsenko, SA | 1 |
Rybczynska, M | 1 |
Liu, R | 1 |
Lu, P | 1 |
Sharom, FJ | 1 |
Steinfels, E | 1 |
Pietro, AD | 1 |
Spitaler, M | 1 |
Grunicke, H | 1 |
Hofmann, J | 1 |
Leonard, R | 1 |
Hardy, J | 1 |
van Tienhoven, G | 1 |
Houston, S | 1 |
Simmonds, P | 1 |
David, M | 1 |
Mansi, J | 1 |
Haberkorn, U | 1 |
Reinhardt, M | 2 |
Strauss, LG | 1 |
Oberdorfer, F | 1 |
Berger, MR | 2 |
Altmann, A | 1 |
Wallich, R | 1 |
Dimitrakopoulou, A | 1 |
van Kaick, G | 1 |
Unger, C | 5 |
Peukert, M | 3 |
Engel, J | 3 |
Eibl, H | 5 |
Rewasowa, EC | 1 |
Büttner, B | 1 |
Becker, M | 1 |
Görlich, M | 1 |
Yanapirut, P | 1 |
Schmähl, D | 1 |
Nagel, G | 2 |
Damenz, W | 1 |
Fleer, EA | 1 |
Kim, DJ | 1 |
Breiser, A | 2 |
von Heyden, HW | 1 |
Nagel, GA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Fluorescent Nanoparticles Conjugated Long-acting Somatostatin Analog for Potent Suppression and Bioimaging Breast Cancer[NCT04138342] | Phase 1 | 30 participants (Anticipated) | Interventional | 2019-09-15 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 review available for miltefosine and Breast Neoplasms
Article | Year |
---|---|
Hexadecylphosphocholine: a new and selective antitumor drug.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Drug Screening Assays, Antitumor; Female; Humans; | 1990 |
5 trials available for miltefosine and Breast Neoplasms
Article | Year |
---|---|
Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dr | 1999 |
Miltefosine as a topical treatment for cutaneous metastases in breast carcinoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Br | 1999 |
Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients.
Topics: Administration, Topical; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Middl | 2000 |
[Treatment with Miltex for metastatic skin lesions in breast cancer] .
Topics: Adult; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Middle Aged; Phosphorylcholine; Skin | 2000 |
Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Do | 2001 |
22 other studies available for miltefosine and Breast Neoplasms
Article | Year |
---|---|
Novel alkylphospholipid-DTC hybrids as promising agents against endocrine related cancers acting via modulation of Akt-pathway.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Ditiocarb; Drug Sc | 2014 |
Enhancing the
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Survival; Chemistry, Pharmaceutica | 2021 |
Distinctive molecular signaling in triple-negative breast cancer cell death triggered by hexadecylphosphocholine (miltefosine).
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Fas Ligand Protein; fas Recept | 2008 |
The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Divisi | 1994 |
Antineoplastic activity of alkylphosphocholines (APC) in human breast carcinomas in vivo and in vitro; use of liposomes.
Topics: Administration, Oral; Adult; Aged; Animals; Antineoplastic Agents; Breast Neoplasms; Dose-Response R | 1994 |
Evidence for abrogation of oncogene-induced radioresistance of mammary cancer cells by hexadecylphosphocholine in vitro.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Survival; Female; Gene Expression Regulation, Neoplast | 1993 |
The effects of hexadecylphosphocholine (HPC) a mixture of alkylphosphocholines (APC) and different dietary oils on the growth of a human mammary tumor.
Topics: Animals; Breast Neoplasms; Corn Oil; Dietary Fats, Unsaturated; Dinoprostone; Fish Oils; Humans; Mic | 1993 |
Miltefosine in recurrent cutaneous breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Phosphorylcholi | 1997 |
Antineoplastic activity of sterically stabilized alkylphosphocholine liposomes in human breast carcinomas.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Cholesterol; Ethanol | 1997 |
IL-1 gene expression in human mammary tumour xenografts after treatment with hexadecylphosphocholine.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Female; Gene Expre | 1997 |
Comparison of hexadecylphosphocholine with fish oil as an antitumor agent.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Dinoprostone; Docosahexaenoic Acids; Drug Combinat | 1997 |
Physical properties and pharmacological activity in vitro and in vivo of optimised liposomes prepared from a new cancerostatic alkylphospholipid.
Topics: Animals; Breast Neoplasms; Cell Division; Female; Humans; Liposomes; Metallothionein 3; Mice; Mice, | 1998 |
Cellular uptake and retention measurements of alkylphosphocholines in the SK-BR-3 breast cancer and Molt-4 leukemia cell line using capillary gas chromatography.
Topics: Antineoplastic Agents; Breast Neoplasms; Chromatography, Gas; Humans; Leukemia; Phosphorylcholine; R | 1999 |
Pharmacokinetics of sterically stabilized hexadecylphosphocholine liposomes versus conventional liposomes and free hexadecylphosphocholine in tumor-free and human breast carcinoma bearing mice.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Chemistry, Pharmaceutical; Disea | 1999 |
MDR1 causes resistance to the antitumour drug miltefosine.
Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Ca | 2001 |
Metabolic design of combination therapy: use of enhanced fluorodeoxyglucose uptake caused by chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromatogra | 1992 |
Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; | 1992 |
Characterization of two human mammary carcinomas, MT-1 and MT-3, suitable for in vivo testing of ether lipids and their derivatives.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Drug Screening Assays, A | 1992 |
In vitro investigations on the antineoplastic effect of hexadecylphosphocholine.
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Breast Neoplasms; Colony-Forming Units Assay; Hum | 1991 |
Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dr | 1990 |
Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Choline; Drug Screening Assays, Antitumor; Female; | 1989 |
Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial.
Topics: Administration, Topical; Breast Neoplasms; Choline; Drug Evaluation; Female; Humans; Neoplasm Recurr | 1988 |